Across trials, ICIs have shown promising intracranial activity in select patients with NSCLC brain metastases, particularly those with PD-L1 expression, minimal neurologic symptoms, and no corticosteroid use. This evidence concerns the gene CD274 and non-small cell lung carcinoma.